Skip to content
Search

Latest Stories

Boots pharmacists receive £750 pro rata bonus

Boots pharmacists receive £750 pro rata bonus

 The PDA secured a 5% pay award for Boots pharmacists during last year’s pay negotiations with the pharmacy chain

Pharmacists working at Boots have been awarded a non-consolidated £750 pro rata payment, following last year’s successful negotiations between the Pharmacists' Defence Association (PDA) Union and Boots UK.


Announcing this development, the PDA highlighted that the payment recognises the dedication of Boots pharmacists in delivering NHS core and advanced services, including the Pharmacy First Service, Common Ailments Service, Hypertension Case Finding and Pharmacy Contraception Service.

“This bonus is a recent example of the successful collaboration between the PDA and Boots, and how working alongside a trade union can benefit all parties involved,” the associated stated.

As the official union for pharmacists at Boots, the PDA plays a crucial role in negotiating their pay, terms, and conditions.

The PDA’s pay negotiations with the pharmacy chain last year led to a five percent pay increase for Boots pharmacists, which came into effect in November 2023.

The union revealed that discussions for the 2024 pay review are currently underway with Boots.

The PDA also has recognition agreements with other employers, including LloydsPharmacy Healthcare Services and all GP Federations in Northern Ireland.

These agreements enable formal negotiations on pay, terms, and conditions between employees and employers.

Pharmacists interested in establishing a recognition agreement at their workplace are encouraged to contact the PDA Member Support Centre for assistance.

Last month, Boots announced that it would proceed with closing the remaining stores as part of its plan to shut 300 UK pharmacy branches by the summer of 2024.

Last month, Boots confirmed to The Pharmaceutical Journal that it would complete the closure of the remaining stores of its planned programme to shut 300 UK pharmacy branches in the summer of 2024.

In June 2023, Walgreens Boots Alliance, Boots' parent company, announced its decision to close 300 UK pharmacies within a year as part of plans to save US$800m.

Currently, Boots UK operates 2,100 stores across the UK.

In its quarterly financial report released on 27 June 2024, Walgreens Boots Alliance said that part of its cost-cutting measure involved the closure of "up to 650 Boots stores" in the UK. By 31 May 2024, the company had closed 581 of these stores.

More For You

Imported dengue reach record high, warns UKSHA

Most dengue cases were linked to travel to Southern and South-Eastern Asia.

Getty Images

Imported dengue cases hit record high – Consult your pharmacist before you travel

The UK Health Security Agency (UKSHA) has warned that imported dengue cases in England, Wales, and Northern Ireland (EWNI) have reached their highest level since dengue surveillance began in 2009.

New data from the agency reveals that 904 dengue cases were reported among returning travellers in these countries in 2024, a sharp increase from 631 in 2023.

Keep ReadingShow less
Henry Gregg named as new NPA chief executive

Henry Gregg (left) with Sir Chris Whitty

Pic credit: Henry Gregg/X

Henry Gregg named as new NPA chief executive

The National Pharmacy Association (NPA) has announced Henry Gregg will be the organisation’s new chief executive from May.

Gregg, who is currently director of external affairs at Asthma + Lung UK, replaces Paul Rees who departed in January.

Keep ReadingShow less
Kelso Pharma continues expansion with £140M funding boost

Kelso Pharma will use the funds to support further acquisitions and expand in the UK and Europe.

Getty Images

Kelso Pharma secures over £140m of acquisition funding

Kelso Pharma has secured more than £140 million of acquisition funding to support its expansion in the UK and across Europe.

The specialty pharmaceuticals business today (27) confirmed that a proportion of the funding was used for its acquisition of ALTURiX last month, a deal that doubled the size of the company’s UK business.

Keep ReadingShow less
Community pharmacist accessing GP Connect Access Record on Cegedim Rx platform

GP Connect Access Record will make a patient’s relevant medical information available to pharmacy.

Getty Images

Cegedim Rx activates GP Connect Access Record

Community pharmacy IT supplier Cegedim Rx has made GP Connect Access Record functionality available across its clinical services platform, providing registered pharmacy professionals with enhanced access to patient medical information.

The new feature, now live on Cegedim Rx’s Pharmacy Services platform, allows community pharmacies to retrieve relevant medical data when delivering NHS clinical services.

Keep ReadingShow less
Prepayment certificates helped patients avoid £837M in prescription fees, NHSBSA analysis reveals

Patients who purchase two prescriptions per month could save more than £110 annually with a 12-month PPC.

Getty Images

Prepayment certificates helped patients avoid £837M in prescription fees, NHSBSA analysis reveals

The NHS Business Services Authority (NHSBSA) has published a new experimental analysis, estimating patient savings achieved from prescription prepayment certificates (PPCs), including Hormone Replacement Therapy (HRT) PPCs.

The report revealed that the number of Prescription Prepayment Certificates (PPCs) purchased has risen consistently over the past five years, with 3.3 million patients receiving NHS prescriptions under a PPC exemption in 2023/2024.

Keep ReadingShow less